Amalgamated Bank Sells 20,978 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Amalgamated Bank trimmed its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 37.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,744 shares of the biotechnology company's stock after selling 20,978 shares during the quarter. Amalgamated Bank's holdings in Arrowhead Pharmaceuticals were worth $455,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Xponance Inc. increased its holdings in Arrowhead Pharmaceuticals by 4.5% in the fourth quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company's stock worth $327,000 after purchasing an additional 744 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in Arrowhead Pharmaceuticals by 2.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company's stock worth $714,000 after purchasing an additional 803 shares in the last quarter. ADAR1 Capital Management LLC increased its holdings in Arrowhead Pharmaceuticals by 10.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company's stock worth $243,000 after purchasing an additional 1,195 shares in the last quarter. GAMMA Investing LLC increased its holdings in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,628 shares in the last quarter. Finally, Swiss National Bank increased its holdings in Arrowhead Pharmaceuticals by 0.8% in the fourth quarter. Swiss National Bank now owns 220,000 shares of the biotechnology company's stock worth $4,136,000 after purchasing an additional 1,700 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Stock Down 2.9%

Arrowhead Pharmaceuticals stock traded down $0.55 during trading on Friday, hitting $18.31. 1,446,983 shares of the company were exchanged, compared to its average volume of 1,564,748. The business's 50 day moving average is $15.79 and its 200 day moving average is $16.39. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41. The company has a market capitalization of $2.53 billion, a P/E ratio of -13.08, a PEG ratio of 22.21 and a beta of 0.93. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.31.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same quarter last year, the company posted ($1.02) EPS. Analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ARWR shares. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Chardan Capital restated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Finally, Citigroup decreased their price objective on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $43.71.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.